US FDA Sending AZ, Other Cancer Sponsors Trial Design Message With Imfinzi AdComm

 
• By Sarah Karlin-Smith
  
Generate a summary of this article
Listen to this article
Beta

The Oncologic Drugs Advisory Committee will vote on a product agnostic question related to perioperative trial designs during a 25 July meeting after discussing whether AstraZeneca needs an additional trial for its Imfinzi perioperative regimen in non-small cell lung cancer.

red bullhorn with sign underneath that says "attention please"
The FDA's 25 July ODAC meeting appears important for many sponsors developing immunotherapies. • Source: Shutterstock

AstraZeneca PLC looks unlikely to nab a supplemental perioperative indication for Imfinzi (durvalumab) in resectable non-small cell lung cancer (NSCLC) after failing to heed FDA’s trial design advice in 2018, briefing documents and an addendum released ahead of a 25 July FDA Oncologic Drugs Advisory Committee Meeting suggest.

Key Takeaways

  • The FDA likely will require an additional trial before approving AstraZeneca’s Imfinzi in resectable NSCLC for perioperative use due to the inability to distinguish whether the drug's efficacy is related to the neoadjuvant phase, the adjuvant phase, or both.

The FDA also appears prepared to use the application as a case study to justify formally requiring different trial designs...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered. 

EU Filings Tracker TEST

New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Global Pharma Guidance Tracker – August 2024

 
• By Vibha Sharma

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.